Lion Biotech (LBIO) Announces FDA Allowance of Its Investigational New Drug

Lion Biotechnologies, Inc. (LBIO), announced that the FDA has allowed its investigational new drug (IND) application to initiate a Phase 2 study of its lead product candidate, LN-144, in the treatment of refractory metastatic melanoma. The single-arm clinical trial will be conducted at up to five sites in a total of 20 evaluable patients with […] View the full post at: Lion Biotech (LBIO) Announces FDA Allowance of Its Investigational New Drug No related posts.